MWNA
JUNO

Marshall Wace North America’s Juno Therapeutics, Inc. JUNO Stock Holding History

Marshall Wace North America’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-36,009
Closed -$1.62M – 1781
2017
Q3 		$1.62M Sell
36,009
-287,081
-89% -$9.79M 0.01% 850
2017
Q2 		$9.69M Buy
+323,090
New +$7.97M 0.07% 330

Other funds holding JUNO

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Marshall Wace North America's JUNO Position: Q4 2017 in Review

Marshall Wace North America sold out of Juno Therapeutics, Inc. (JUNO) in Q4 2017, closing a stake of 36,009 shares — an estimated $1.62M sold.

Marshall Wace North America first reported a position in JUNO in Q2 2017 and held it in 2 quarters. The position peaked at $9.69M in Q2 2017. 237 funds tracked by Wall St. Rank hold JUNO as of Q4 2017.

  • Marshall Wace North America reported no remaining Juno Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • Marshall Wace North America sold 36,009 Juno Therapeutics, Inc. shares in Q4 2017, an estimated $1.62M.
  • Marshall Wace North America first reported a position in Juno Therapeutics, Inc. in Q2 2017 and held it in 2 quarters.
  • Marshall Wace North America's Juno Therapeutics, Inc. position peaked at $9.69M in Q2 2017.
  • 237 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q4 2017.

Based on Marshall Wace North America's 13F filing for Q4 2017, filed 14 Feb 2018.